As personalized nutrition grows, experts argue t

Lausanne-based Vandria presented multiple ascendi

Winona, a physician-led telehealth company focuse

Immorta Bio published a peer-reviewed Perspective

i-Lumen Scientific, a clinical-stage medical tech

California-based Frontier Bio was named a Phase 1

D&D Pharmatech reported publication in Lancet Gas

NeuroSense intends to proceed with a New Drug Sub

The Emerald update redesigns the app around acti

Federal court ruling highlights growing pressure

Federal court ruling highlights growing pressure

Wellthspan Advisory’s Nadine Esposito explains

New UAE-backed venture bets future of longevity

Cumulus Neuroscience and Muse bring lab-grade sl

As investment fuels brain diagnostics, Amprion’s expansion highlights growing belief that better tests are just as important as better drugs. The race against neurodegenerative disease has largely focused on finding the next breakthrough drug. However, a growing number of researchers are beginning to ask a different question: what if one of the biggest bottlenecks isn’t the medicine, but knowing exactly who should receive it? That question sits at the heart of two conversations reshaping the field. The first is about de-risking drug development. Every failed clinical trial represents years of work and billions of dollars, but sometimes a promising therapy isn’t what fails. Sometimes the wrong patients are enrolled because diagnosing diseases like Parkinson’s or Lewy body dementia remains remarkably difficult, particularly in their early stages. Companies like Amprion are increasingly becoming the gateway that helps biopharma identify the right patients before a trial even begins. If that’s true, could expanding diagnostic capacity ultimately help speed the arrival of disease-modifying therapies? The second conversation is even broader. As medicine shifts toward detecting disease before symptoms become severe, biomarkers – the measurable biological signs that reveal what’s happening inside the body – have become one of healthcare’s hottest currencies. Companies that…

Swiss-developed system brings longitudinal blood

Debut and Natura team up to develop an AI-discov

True cellular therapeutics require stem cells bu

Report says performance health startup winding d

New platform reflects growing demand for persona

Pilot research suggests Basis may ease menopausa

FDA clearance for all skin types is making regen

New assay could make tracking Alzheimer’s prog

Preventive health platform will use new funding

AIA and BCA are turning preventive longevity int

Funding backs new diagnostics platform as the co

Avaí Bio completes a manufacturing step that co

Dubai’s new longevity authority could reshape

As AI becomes increasingly capable of interpreti

Lighthouse Pharmaceuticals presented new analyses

Biogen and Ionis presented Phase 2 CELIA results

BioAge Labs has dosed the first participant in QU

Halia Therapeutics announced two posters at the A

Tenpoint Therapeutics has submitted a Marketing A

ImmunoBrain announced that Phase 1b data for IBC-

ProMIS presented data at the Alzheimer’s Associ

New analyses suggest Alzheon’s therapy may pro

The startup is betting that the future of longev

Eisai and Biogen presented data at the Alzheimer’s Association International Conference 2026 in London showing that a lecanemab subcutaneous autoinjector (LEQEMBI) produced exposure, efficacy and safety comparable to the approved intravenous initiation regimen in people with early Alzheimer’s disease. According to the company, once-weekly 500 mg subcutaneous administration demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks) with an exposure ratio of 104% (90% confidence interval 99.1%–109%) and consistent exposure across body weight quartiles. The companies claim that amyloid reduction measured by PET, clinical efficacy on CDR-SB and incidence of ARIA-E were driven by lecanemab exposure rather than route of administration. Safety findings were generally consistent with the IV formulation; injection-related reactions were mostly localized, predicted ARIA-E incidence was similar, and anti-drug antibodies occurred in 1.4% of patients with no neutralizing antibodies observed. Early clinical and real-world data from two U.S. centers indicated slower cognitive decline on CDR-SB over 36 months in a 28-patient cohort versus a matched natural history cohort, and 10 of 11 evaluable patients in a separate series improved or remained stable on MMSE after maintenance therapy. The company reports high patient and care partner satisfaction and notes flexibility to switch between IV and…

Cognito Therapeutics presented exploratory cerebr

At the Alzheimer’s Association International Co

NeuroTherapia will present data from its recently

Indiana University and PharmatrophiX presented a

Aeon welcomed the establishment of the Dubai Long

Eisai presented data at the Alzheimer’s Associa

The New England Journal of Medicine published a p

New study shows long-assumed irreversible AGEs c

Positive Phase 3 results hint that the next obes

Chinese biotech’s universal CAR-T therapy secu

As experimental cell therapy heads to BIOCHINA,